Tirzepatide
Tirzepatide is a novel dual GIP/GLP-1 receptor agonist that leverages two incretin pathways simultaneously, representing a breakthrough in metabolic regulation through unimolecular dual agonism.
Tirzepatide demonstrates balanced activation of both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, producing synergistic effects on insulin secretion, glucagon suppression, and appetite regulation beyond single-pathway activation.
Research shows superior metabolic outcomes with up to 20.9% weight reduction and 2.4% HbA1c reduction in clinical models, exceeding results from selective GLP-1 agonists alone.
Studies reveal unique effects on lipid metabolism with 25% triglyceride reduction and significant hepatic fat clearance through combined incretin signaling and enhanced insulin sensitivity.
Tirzepatide achieves dual incretin activation, unprecedented weight loss, and comprehensive metabolic improvement, offering researchers a next-generation tool for investigating obesity, type 2 diabetes, and metabolic syndrome.
Composition: Tirzepatide (15 mg, 30mg)